검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | BAY 73-4506 (Regorafenib, Regorafenib (BAY 73-4506)) Zhejiang University·Metastatic Colorectal Cancer (mCRC… ORR 20% |
|---|---|
Overview Program | Regorafenib (BAY 73-4506) |
Overview Company | Zhejiang University |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Colorectal Cancer (mCRC) |
Overview Indication | Hepatocellular Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Biomarker | HER2-positive, MSI-H/dMMR, and rare fusion-positive |
PK/PD Species | Rat, Human |
PK/PD Animal (cat.) | Human, Rat |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | Rat, Human |
Toxicology Animal (cat.) | Human, Rat |
Toxicology Major finding | Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis.. Trifluridine/tipiracil (TAS-102) and regorafenib are approved and widely utilized as later-line treatment options for patients with metastatic colorectal cancer (mCRC). However, the optimal sequence between these agents remains … |
Clinical Primary efficacy | ORR 20% |
Clinical ORR | 20.0% |
Clinical PFS | 5.1 |
Clinical OS | 7.5 |
Clinical Result source | ClinicalTrials.gov NCT03992456 |
Clinical Data Tier / Score | A · 45 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | BAY 73-4506 (Regorafenib, Regorafenib (BAY 73-4506)) Zhejiang University·Metastatic Colorectal Cancer (mCRC… ORR 20% |
|---|---|
Overview Program | Regorafenib (BAY 73-4506) |
Overview Company | Zhejiang University |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Colorectal Cancer (mCRC) |
Overview Indication | Hepatocellular Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Biomarker | HER2-positive, MSI-H/dMMR, and rare fusion-positive |
PK/PD Species | Rat, Human |
PK/PD Animal (cat.) | Human, Rat |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | Rat, Human |
Toxicology Animal (cat.) | Human, Rat |
Toxicology Major finding | Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis.. Trifluridine/tipiracil (TAS-102) and regorafenib are approved and widely utilized as later-line treatment options for patients with metastatic colorectal cancer (mCRC). However, the optimal sequence between these agents remains … |
Clinical Primary efficacy | ORR 20% |
Clinical ORR | 20.0% |
Clinical PFS | 5.1 |
Clinical OS | 7.5 |
Clinical Result source | ClinicalTrials.gov NCT03992456 |
Clinical Data Tier / Score | A · 45 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교